Dual versus triple antithrombotic therapy: is there a role for direct oral anticoagulants in arterial thrombosis?
-
Álvaro García-Ropero [1] ; Carlos Garcia Santos-Gallego [1] ; Mohammad Urooj Zafar [1] ; Juan Jose Badimon [1]
-
[1] Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
Estados Unidos
-
- Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 55, Nº. 3, 2019, págs. 197-214
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
The number of patients receiving dual antiplatelet therapy with an additional indication for long-term oral anticoagulation has substantially increased over time. This population is facing an unacceptable risk of bleeding events, particularly among elderly individuals, who are especially vulnerable to complications. Further strategies to minimize this bleeding risk, including various drug combinations, different dosage regimens and even numerous attempts to find the appropriate duration of the treatment, have been evaluated in a multitude of randomized control trials. Moreover, the recent incorporation of the direct oral anticoagulants (DOACs) to the therapeutic armamentarium may represent an alternative to treat such patients, since they have demonstrated to be noninferior to the classic vitamin K antagonists and with lower bleeding rates. The aim of this review is to summarize the most recent literature on the use of DOACs in patients with an indication for dual antiplatelet therapy (mostly subjects with coronary artery disease) and also an established indication for chronic anticoagulation (chiefly individuals with nonvalvular atrial fibrillation). The role of DOACs in ischemic heart disease alone is also discussed.
